Influenza A virus H1N1 vaccine - Hard To Treat Diseases

Drug Profile

Influenza A virus H1N1 vaccine - Hard To Treat Diseases

Alternative Names: Swine flu vaccine - Hard To Treat Diseases/Mellow Hope/Zhejiang Tianyuan Bio-pharmaceutical

Latest Information Update: 02 Apr 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Hard To Treat Diseases
  • Class Influenza A virus H1N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Influenza A virus H1N1 subtype

Most Recent Events

  • 22 Mar 2011 Zhejiang Tianyuan Bio-pharmaceutical has been acquired by Novartis
  • 19 Nov 2009 Registered for Influenza-A virus H1N1 subtype in Chile (Parenteral)
  • 29 Sep 2009 Registered for Influenza-A virus H1N1 subtype in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top